AlivaMab Discovery Services Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AlivaMab Discovery Services's estimated annual revenue is currently $8.5M per year.(i)
  • AlivaMab Discovery Services's estimated revenue per employee is $155,000

Employee Data

  • AlivaMab Discovery Services has 55 Employees.(i)
  • AlivaMab Discovery Services grew their employee count by 62% last year.

AlivaMab Discovery Services's People

NameTitleEmail/Phone
1
Founder and CEOReveal Email/Phone
2
VP at AlivaMab Discovery ServicesReveal Email/Phone
3
VP, Antibody Engineering and Protein SciencesReveal Email/Phone
4
VP Business DevelopmentReveal Email/Phone
5
Head PMOReveal Email/Phone
6
Associate Director, Antibody DiscoveryReveal Email/Phone
7
Associate DirectorReveal Email/Phone
8
DirectorReveal Email/Phone
9
Associate Director, Antibody DiscoveryReveal Email/Phone
10
Director Human ResourcesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is AlivaMab Discovery Services?

AlivaMab Discovery Services was established by Ablexis in response to many prospective partners wanting to outsource discovery to a scientifically-driven organization led by a team with in-the-trenches experience and real understanding of therapeutic antibody discovery and development. AlivaMab Discovery Services leverages the AlivaMab Mouse, developed by Ablexis as the platform for discovery projects conducted on behalf of clients. For more information, visit www.alivamab.com.

keywords:N/A

N/A

Total Funding

55

Number of Employees

$8.5M

Revenue (est)

62%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.4M5541%N/A
#2
$13.4M554%N/A
#3
$7.2M55N/AN/A
#4
$7.2M55N/AN/A
#5
$6.9M55-10%$2M